We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

55 hedge funds and large institutions have $40.4M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

274% more call options, than puts

Call options by funds: $654K | Put options by funds: $175K

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

29% more capital invested

Capital invested by funds: $31.3M → $40.4M (+$9.16M)

7% less funds holding

Funds holding: 59 → 55 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
1.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
4
Increased
19
Reduced
13
Closed
8
Calls
$654K
Puts
$175K
Net Calls
+$479K
Net Calls Change
-$302K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$4.45M
2
BI
BVF Inc
California
+$2.03M
3
NMC
NEA Management Company
Maryland
+$1.87M
4
BBA
Baker Bros. Advisors
New York
+$1.11M
5
DCM
Driehaus Capital Management
Illinois
+$775K

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$2.49M
2
PA
Perceptive Advisors
New York
-$567K
3
QSS
Quantitative Systematic Strategies
Florida
-$305K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$273K
5
GTC
Ghost Tree Capital
New York
-$237K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
26
Anson Funds Management
Texas
$40K +$40K +214 New
JP Morgan Chase
27
JP Morgan Chase
New York
$38K +$16.8K +90 +82%
NFG
28
Noven Financial Group
Colorado
$37K +$13.3K +71 +57%
WMSA
29
Weiss Multi-Strategy Advisers
New York
$36K -$561 -3 -2%
State Street
30
State Street
Massachusetts
$25K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$20K -$7.86K -42 -28%
Citadel Advisors
32
Citadel Advisors
Florida
$14K +$1.5K +8 +12%
BA
33
BlackRock Advisors
Delaware
$13K – – –
VKH
34
Virtu KCG Holdings
New York
$11K -$80.1K -428 -88%
TSS
35
Two Sigma Securities
New York
$11K -$14.4K -77 -57%
Simplex Trading
36
Simplex Trading
Illinois
$10K -$2.62K -14 -20%
GC
37
Guggenheim Capital
Illinois
$10K – – –
NFC
38
Northeast Financial Consultants
Connecticut
$10K – – –
BIM
39
BlackRock Investment Management
Delaware
$10K +$935 +5 +10%
Bank of America
40
Bank of America
North Carolina
$10K +$4.3K +23 +79%
CCM
41
Chilton Capital Management
Texas
$9K – – –
Wells Fargo
42
Wells Fargo
California
$6K -$3.18K -17 -33%
TRCT
43
Tower Research Capital (TRC)
New York
$6K +$6.17K +33 New
AIM
44
Advantage Investment Management
Iowa
$2K – – –
WA
45
Winfield Associates
Ohio
$2K – – –
Citigroup
46
Citigroup
New York
$2K +$1.5K +8 +133%
HDIM
47
Hanson & Doremus Investment Management
Vermont
$1K – – –
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$1K – – –
CG
49
Cutler Group
California
$1K +$1.12K +6 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 – – –
1
2
3

VIRX Hedge Fund Activity: Q4 2015 in Review

55 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2015, worth a combined $40.4M — up 29% from $31.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of VIRX and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 19 added.

The largest buyer was Great Point Partners, adding an estimated $4.45M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.49M sold.

  • 55 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2015, down from 59 in Q3 2015.
  • Funds reported $40.4M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2015, up 29% quarter-over-quarter.
  • 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2015 and 8 closed out, a net change of -4 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2015 was Great Point Partners, an estimated $4.45M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2015 was Farallon Capital Management, an estimated $2.49M sold.

Based on aggregated 13F filings for Q4 2015.